MBB Public Markets I LLC purchased a new stake in Bio-Techne Corp (NASDAQ:TECH - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 5,216 shares of the biotechnology company's stock, valued at approximately $306,000.
Other hedge funds have also bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its position in Bio-Techne by 17.9% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 19,630 shares of the biotechnology company's stock valued at $1,153,000 after purchasing an additional 2,980 shares during the period. Teacher Retirement System of Texas bought a new stake in shares of Bio-Techne in the 1st quarter worth $1,362,000. GAMMA Investing LLC grew its stake in shares of Bio-Techne by 3,534.0% in the 1st quarter. GAMMA Investing LLC now owns 105,241 shares of the biotechnology company's stock worth $6,170,000 after acquiring an additional 102,345 shares in the last quarter. CX Institutional bought a new stake in shares of Bio-Techne in the 1st quarter worth $27,000. Finally, State of Alaska Department of Revenue grew its stake in shares of Bio-Techne by 2.2% in the 1st quarter. State of Alaska Department of Revenue now owns 18,524 shares of the biotechnology company's stock worth $1,086,000 after acquiring an additional 405 shares in the last quarter. Institutional investors and hedge funds own 98.95% of the company's stock.
Wall Street Analysts Forecast Growth
TECH has been the subject of several recent analyst reports. Citigroup upgraded shares of Bio-Techne from a "neutral" rating to a "buy" rating and upped their target price for the stock from $55.00 to $70.00 in a research note on Thursday, August 21st. Stephens upgraded shares of Bio-Techne to a "strong-buy" rating and set a $65.00 target price for the company in a research note on Tuesday, July 22nd. Royal Bank Of Canada upgraded shares of Bio-Techne from a "hold" rating to a "moderate buy" rating in a research note on Wednesday, September 3rd. Wells Fargo & Company initiated coverage on shares of Bio-Techne in a research note on Friday, May 30th. They issued an "overweight" rating and a $59.00 target price for the company. Finally, Benchmark reiterated a "buy" rating and issued a $75.00 target price on shares of Bio-Techne in a research note on Thursday, June 5th. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $70.42.
Check Out Our Latest Research Report on TECH
Bio-Techne Price Performance
Shares of NASDAQ:TECH opened at $50.96 on Thursday. The company's 50-day moving average is $53.95 and its 200 day moving average is $53.54. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.38 and a current ratio of 3.46. The company has a market capitalization of $7.99 billion, a P/E ratio of 110.79, a price-to-earnings-growth ratio of 3.46 and a beta of 1.47. Bio-Techne Corp has a fifty-two week low of $46.01 and a fifty-two week high of $80.95.
Bio-Techne (NASDAQ:TECH - Get Free Report) last issued its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.53 earnings per share for the quarter, topping analysts' consensus estimates of $0.50 by $0.03. The company had revenue of $316.96 million for the quarter, compared to the consensus estimate of $315.14 million. Bio-Techne had a net margin of 6.02% and a return on equity of 13.43%. The firm's quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.49 EPS. On average, equities research analysts forecast that Bio-Techne Corp will post 1.67 earnings per share for the current year.
Bio-Techne Announces Dividend
The company also recently disclosed a quarterly dividend, which was paid on Friday, August 29th. Investors of record on Monday, August 18th were paid a $0.08 dividend. This represents a $0.32 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date was Monday, August 18th. Bio-Techne's payout ratio is currently 69.57%.
Bio-Techne Profile
(
Free Report)
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research and clinical diagnostic markets in the United States, the United Kingdom, rest of Europe, Middle East, and Africa, Greater China, rest of Asia-Pacific, and internationally.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bio-Techne, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bio-Techne wasn't on the list.
While Bio-Techne currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
